Live Breaking News & Updates on Breakthrough Campus

Stay updated with breaking news from Breakthrough campus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

EQT Private Equity to sell Aldevron to Danaher Corporation for enterprise value of USD 9.6 billion

EQT Private Equity to sell Aldevron to Danaher Corporation for enterprise value of USD 9.6 billion
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , North Dakota , Stephanie Greengarten , Michael Chambers , John Ballantyne , Kevin Ballinger , Eric Liu , Global Co , Aldevron To Danaher Corporation , Simpson Thacher Bartlett , Aldevron Press , Morgan Stanley Co , Ta Associates , Danaher Corporation , Breakthrough Campus , Executive Chairman , Global Co Head , Simpson Thacher , ஒன்றுபட்டது மாநிலங்களில் , வடக்கு டகோட்டா , மைக்கேல் அறைகள் , ஜான் பல்லாண்ட்டின் , கெவின் பாலிங்கர் , எரிக் லியூ , உலகளாவிய இணை , சிம்ப்சன் தாச்சர் பார்ட்லெட் ,

Moderna and Aldevron Expand Collaboration

The focus will be on Moderna’s COVID-19 vaccine and additional programs in its clinical development pipeline. ....

Juan Andres , Ellen Shafer , Kevin Ballinger , Breakthrough Campus , Advance Campus , Madison Campus , ஜுவான் அன்றேல் , எல்லன் ஷாபெர் , கெவின் பாலிங்கர் , மாடிசன் வளாகம் ,

Samsung Biologics to provide fill-finish manufacturing for Moderna's COVID-19 vaccine

Samsung Biologics to provide fill-finish manufacturing for Moderna’s COVID-19 vaccine
Samsung Biologics will provide large-scale fill-finish manufacturing for Moderna’s COVID-19 vaccine from its facilities in South Korea.
Upon execution of the deal, technology transfer will commence immediately. Samsung Biologics’ Incheon facilities will use a state-of-the-art production line equipped for aseptic fill-finish, labeling, and packaging services.
The agreement will support the production of hundreds of millions of doses of Moderna’s COVID-19 vaccine, destined to supply of markets outside of the US.
John Rim, CEO of Samsung Biologics, said:
“Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021.” ....

United States , Switzerland General , North Dakota , South Korea , Republic Of Korea , Samsung Biologics , Prevention Agency , Korea National Institute Of Health , Korea Centers For Disease , Ministry Of Health , Ministry Of Food , Biologic Incheon , Korea National Institute , Korea Centers , Disease Control , Drug Safety , Conditional Marketing Authorization , Breakthrough Campus , Downstream Processing , Samsung Biologics , Covid 19 Vaccine , South Korea , ஒன்றுபட்டது மாநிலங்களில் , சுவிட்சர்லாந்து ஜநரல் , வடக்கு டகோட்டா , தெற்கு கொரியா ,